Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT05370430 · PeproMene Bio, Inc.

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

What this study is about

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

View original scientific description

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Informed Consent: Signed informed consent by the participant or legally authorized representative.
  • Age \& Performance Status:
  • Age ≥ 18 years
  • ECOG performance status ≤ 2
  • Diagnosis \& Disease Criteria:
  • Histologically confirmed B-NHL, including LBCL, MCL, and FL/MZL subtypes meeting specified prior treatment conditions.
  • BAFF-R expression on lymphoma cells required.
  • Measurable Disease: Tumor ≥1.5 cm on CT/PET scan or evidence of disease in blood, BM, GI, skin, or spleen.
  • Prior CAR T-cell Therapy: Allowed if ≥ 3 months since last treatment and CD19 CAR-T persistence \< 5% before leukapheresis.
  • Organ Function \& Laboratory Criteria:
  • Hematologic: ANC ≥ 1000/μL, Platelets ≥ 75,000/μL (exceptions for BM involvement).
  • Liver Function: Bilirubin ≤ 1.5x ULN (except Gilbert's), AST/ALT \< 3x ULN.
  • Renal Function: CrCl ≥ 50 mL/min.
  • Cardiac \& Pulmonary: LVEF ≥ 45%, QTcF ≤ 480 ms, O₂ saturation \> 91% on room air.
  • Infectious Disease Screening: Seronegative for HIV, active HBV, active HCV (or undetectable viral load if positive).
  • Reproductive Considerations:
  • Negative pregnancy test for females of childbearing potential.
  • Use of effective contraception or abstinence through 3 months post-treatment.

Exclusion criteria

  • Prior Therapies \& Transplants:
  • Prior allogeneic SCT.
  • Autologous SCT \< 6 months before leukapheresis.
  • Concurrent systemic steroids or chronic immunosuppressant use.
  • Disease-Specific Exclusions:
  • Cardiac lymphoma involvement.
  • Need for urgent therapy due to tumor-related complications (e.g., bowel obstruction).
  • Medical Conditions:
  • Active autoimmune disease requiring immunosuppressants.
  • Primary immunodeficiency.
  • Cardiac conditions, including NYHA Class III/IV heart disease, arrhythmia, recent MI (≤ 6 months), stroke (≤ 6 months), or significant VTE (≤ 6 months).
  • Neurologic conditions, including prior optic neuritis, CNS inflammatory diseases, or seizure disorders.
  • History of malignancy, unless resected/treated with curative intent or in remission for ≥ 3 years.
  • Uncontrolled systemic infections or active CNS lymphoma.
  • Pregnancy \& Breastfeeding: Females who are pregnant or nursing.
  • Other Considerations:
  • Investigator-determined safety concerns.
  • Potential noncompliance with study procedures.

Where

  • Duarte, California
  • Stanford, California
  • Kansas City, Kansas
  • Minneapolis, Minnesota
  • Charlotte, North Carolina
  • Seattle, Washington

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Nov 20, 2025 · Source of record for eligibility and locations

📊
1 of 36 participants interested
3% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Duarte

California

Location available
RECRUITING

Stanford

California

Location available
RECRUITING

Kansas City

Kansas

Location available
RECRUITING

Minneapolis

Minnesota

Location available
RECRUITING

Charlotte

North Carolina

Location available
RECRUITING

Seattle

Washington

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Lymphoma Trials by City

Browse all lymphoma clinical trials in these cities — not just this study.

Looking for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Treatment in Duarte?

Join others in California exploring innovative treatment options through clinical research

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Treatment Options in Duarte, California

If you're searching for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma treatment in Duarte, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Duarte, Stanford, Kansas City and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 36 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05370430. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.